Neurocrine Biosciences, Inc. (NBIX)
165.30
+2.18
(+1.34%)
USD |
NASDAQ |
Jun 09, 16:00
167.00
+1.70
(+1.03%)
After-Hours: 20:00
Neurocrine Biosciences SG&A Expense (Quarterly) : 318.50M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Biogen, Inc. | 607.30M |
| Amgen, Inc. | 1.602B |
| Iovance Biotherapeutics, Inc. | 38.95M |
| Voyager Therapeutics, Inc. | 8.261M |
| Incyte Corp. | 328.09M |